EGFR-IN-47

• UNSPSC Description:

  EGFR-IN-47 is a potent and orally active EGFRL858R/T790M/C797S inhibitor with an IC50 of 0.01 μM. EGFR-IN-47 induces cell cycle attest and cell apoptosis. EGFR-IN-47 has the potential for the research of NSCLC[1].

• Target Antigen:

  Apoptosis; EGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/egfr-in-47.html

• Solubility:

  DMSO : 20 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CN(CC1)CCN1C2=CC=C(C=C2)NC3=NC=C4C=C(N(C4=N3)C5CCCC5)CNC6=CC=CC=C6

• Molecular Weight:

  481.64

• References & Citations:

  [1]Wang C, et al. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment. Eur J Med Chem. 2022; 237:114381.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3034649-73-2